These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 32822790)

  • 1. Evaluation of SARS-CoV-2 antibodies in 24 patients presenting with chilblains-like lesions during the COVID-19 pandemic.
    Stavert R; Meydani-Korb A; de Leon D; Osgood R; Blau J; Luu T
    J Am Acad Dermatol; 2020 Dec; 83(6):1753-1755. PubMed ID: 32822790
    [No Abstract]   [Full Text] [Related]  

  • 2. All that glisters is not COVID: Low prevalence of seroconversion against SARS-CoV-2 in a pediatric cohort of patients with chilblain-like lesions.
    Denina M; Pellegrino F; Morotti F; Coppo P; Bonsignori IM; Garazzino S; Ravanini P; Avolio M; Cavallo R; Bertolotti L; Felici E; Acucella G; Montin D; Rabbone I; Licciardi F
    J Am Acad Dermatol; 2020 Dec; 83(6):1751-1753. PubMed ID: 32781180
    [No Abstract]   [Full Text] [Related]  

  • 3. Chilblains-like dermatologic manifestation of COVID-19 diagnosed by serology via multidisciplinary virtual care.
    Kerber AA; Soma DB; Youssef MJ
    Int J Dermatol; 2020 Aug; 59(8):1024-1025. PubMed ID: 32496578
    [No Abstract]   [Full Text] [Related]  

  • 4. Lack of association between chilblains outbreak and severe acute respiratory syndrome coronavirus 2: Histologic and serologic findings from a new immunoassay.
    Hébert V; Duval-Modeste AB; Joly P; Lemée V; Cellier L; Jouen F; Veber B; Drouot L; Boyer O
    J Am Acad Dermatol; 2020 Nov; 83(5):1434-1436. PubMed ID: 32682889
    [No Abstract]   [Full Text] [Related]  

  • 5. Chilblain-like lesions during the COVID-19 pandemic: a serological study on a case series.
    Rizzoli L; Collini L; Magnano M; Termine S; Barcelli R; Infusino SD; Bauer P; Rech G; Girardelli CR; Balestri R
    Br J Dermatol; 2020 Oct; 183(4):782-784. PubMed ID: 32613620
    [No Abstract]   [Full Text] [Related]  

  • 6. A COVID-19 Patient with Repeatedly Undetectable SARS-CoV-2 Antibodies.
    Goetz L; Yang J; Greene W; Zhu Y
    J Appl Lab Med; 2020 Nov; 5(6):1401-1405. PubMed ID: 32745181
    [No Abstract]   [Full Text] [Related]  

  • 7. Chilblain-like lesions during the COVID-19 pandemic: should we really worry?
    Piccolo V; Neri I; Manunza F; Mazzatenta C; Bassi A
    Int J Dermatol; 2020 Aug; 59(8):1026-1027. PubMed ID: 32496583
    [No Abstract]   [Full Text] [Related]  

  • 8. Covid-19 antibody tests: a briefing.
    Baraniuk C
    BMJ; 2020 Jun; 369():m2284. PubMed ID: 32580937
    [No Abstract]   [Full Text] [Related]  

  • 9. Approach to Chilblains During the COVID-19 Pandemic [Formula: see text].
    Ladha MA; Luca N; Constantinescu C; Naert K; Ramien ML
    J Cutan Med Surg; 2020; 24(5):504-517. PubMed ID: 32741218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chilblain-like lesions during the COVID-19 pandemic: early or late sign?
    Recalcati S; Fantini F
    Int J Dermatol; 2020 Aug; 59(8):e268-e269. PubMed ID: 32572958
    [No Abstract]   [Full Text] [Related]  

  • 11. Cross-Comparison of a Chemiluminescent Platform and a Commercial Receptor Binding Domain-Based ELISA for Detecting SARS-CoV-2 IgG.
    Antoine-Reid T; Malone J; Maris AS; White-Abell J; Schmitz JE
    J Appl Lab Med; 2020 Nov; 5(6):1416-1420. PubMed ID: 32750140
    [No Abstract]   [Full Text] [Related]  

  • 12. New insights in COVID-19-associated chilblains: A comparative study with chilblain lupus erythematosus.
    Battesti G; El Khalifa J; Abdelhedi N; Ferre V; Bouscarat F; Picard-Dahan C; Brunet-Possenti F; Collin G; Lavaud J; Le Bozec P; Rousselot M; Tournier A; Lheure C; Couvelard A; Hacein-Bey-Abina S; Abina AM; Charpentier C; Mignot S; Nicaise P; Descamps D; Deschamps L; Descamps V
    J Am Acad Dermatol; 2020 Oct; 83(4):1219-1222. PubMed ID: 32622895
    [No Abstract]   [Full Text] [Related]  

  • 13. Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing.
    Le Cleach L; Dousset L; Assier H; Fourati S; Barbarot S; Boulard C; Bourseau Quetier C; Cambon L; Cazanave C; Colin A; Kostrzewa E; Lesort C; Levy Roy A; Lombart F; Marco-Bonnet J; Monfort JB; Samimi M; Tardieu M; Wolkenstein P; Sbidian E; Beylot-Barry M;
    Br J Dermatol; 2020 Nov; 183(5):866-874. PubMed ID: 32628270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The early antibody response to SARS-Cov-2 infection.
    Dittadi R; Afshar H; Carraro P
    Clin Chem Lab Med; 2020 Sep; 58(10):e201-e203. PubMed ID: 32639941
    [No Abstract]   [Full Text] [Related]  

  • 15. High Incidence of False-Positive Results in Patients with Acute Infections Other than COVID-19 by the Liaison SARS-CoV-2 Commercial Chemiluminescent Microparticle Immunoassay for Detection of IgG Anti-SARS-CoV-2 Antibodies.
    Boukli N; Le Mene M; Schnuriger A; Cuervo NS; Laroche C; Morand-Joubert L; Gozlan J
    J Clin Microbiol; 2020 Oct; 58(11):. PubMed ID: 32848041
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of an Electrochemiluminescent SARS-CoV-2 Antibody Assay.
    Lau CS; Hoo SP; Yew SF; Ong SK; Lum LT; Heng PY; Tan JG; Wong MS; Aw TC
    J Appl Lab Med; 2020 Nov; 5(6):1313-1323. PubMed ID: 32717060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dermoscopy of chilblain-like lesions during the COVID-19 outbreak: A multicenter study on 10 patients.
    Piccolo V; Bassi A; Argenziano G; Mazzatenta C; Guglielmo A; Patrizi A; Neri I
    J Am Acad Dermatol; 2020 Dec; 83(6):1749-1751. PubMed ID: 33010953
    [No Abstract]   [Full Text] [Related]  

  • 18. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients.
    Yu HQ; Sun BQ; Fang ZF; Zhao JC; Liu XY; Li YM; Sun XZ; Liang HF; Zhong B; Huang ZF; Zheng PY; Tian LF; Qu HQ; Liu DC; Wang EY; Xiao XJ; Li SY; Ye F; Guan L; Hu DS; Hakonarson H; Liu ZG; Zhong NS
    Eur Respir J; 2020 Aug; 56(2):. PubMed ID: 32398307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma.
    Yasuda H; Tsukune Y; Watanabe N; Sugimoto K; Uchimura A; Tateyama M; Miyashita Y; Ochi Y; Komatsu N
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):774-776. PubMed ID: 32933879
    [No Abstract]   [Full Text] [Related]  

  • 20. Multi-Platform Comparison of SARS-CoV-2 Serology Assays for the Detection of COVID-19.
    Suhandynata RT; Hoffman MA; Kelner MJ; McLawhon RW; Reed SL; Fitzgerald RL
    J Appl Lab Med; 2020 Nov; 5(6):1324-1336. PubMed ID: 32766840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.